Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Molecular Neurodegeneration|February 10, 2012
WldS but not Nmnat1 protects dopaminergic neurites from MPP+ neurotoxicityJo Ann V Antenor-Dorsey, Karen L O'Malley
The Journal of Urology|August 21, 2002
Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. rangeKimberly A Roehl, Jo Ann V Antenor, William J Catalona
The Journal of Urology|May 7, 2002
Serial biopsy results in prostate cancer screening studyKimberly A Roehl, Jo Ann V Antenor, William J Catalona
The Journal of Urology|January 10, 2004
Clinical value of longitudinal free-to-total prostate specific antigen ratio slope to diagnosis of prostate cancerHui Zhu, Kimberly A Roehl, Jo Ann V Antenor, et al.
Urology|September 6, 2005
Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysisHui Zhu, Kimberly A Roehl, Jo Ann V Antenor, et al.
The Journal of Urology|October 24, 2002
Screening for prostate cancer in high risk populationsWilliam J Catalona, Jo Ann V Antenor, Kimberly A Roehl, et al.
The Journal of Urology|July 12, 2005
Results of compliance with prostate cancer screening guidelinesRobert L Grubb, Kimberly A Roehl, Jo Ann V Antenor, et al.
The Journal of Urology|December 14, 2004
Accuracy of prostate weight estimation by digital rectal examination versus transrectal ultrasonographyStacy Loeb, Misop Han, Kimberly A Roehl, et al.
The Journal of Urology|November 7, 2006
Characteristics of patients with familial versus sporadic prostate cancerKimberly A Roehl, Stacy Loeb, Jo Ann V Antenor, et al.
Archives of Physical Medicine and Rehabilitation|June 17, 2003
Overwork weakness in Charcot-Marie-Tooth diseasePaolo Vinci, Carolina Esposito, Sandra L Perelli, et al.
Pageof 4